KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Amgen (AMGN) over the last 13 years, with Q3 2025 value amounting to -$30.0 million.

  • Amgen's Deferred Taxes rose 7272.73% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year increase of 3170.73%. This contributed to the annual value of -$1.2 billion for FY2024, which is 353.5% up from last year.
  • Latest data reveals that Amgen reported Deferred Taxes of -$30.0 million as of Q3 2025, which was up 7272.73% from -$422.0 million recorded in Q2 2025.
  • Amgen's Deferred Taxes' 5-year high stood at -$30.0 million during Q3 2025, with a 5-year trough of -$623.0 million in Q4 2023.
  • Over the past 5 years, Amgen's median Deferred Taxes value was -$251.0 million (recorded in 2022), while the average stood at -$255.5 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first skyrocketed by 8047.81% in 2023, then tumbled by 71836.73% in 2024.
  • Amgen's Deferred Taxes (Quarter) stood at -$189.0 million in 2021, then crashed by 85.71% to -$351.0 million in 2022, then tumbled by 77.49% to -$623.0 million in 2023, then skyrocketed by 46.39% to -$334.0 million in 2024, then skyrocketed by 91.02% to -$30.0 million in 2025.
  • Its Deferred Taxes stands at -$30.0 million for Q3 2025, versus -$422.0 million for Q2 2025 and -$250.0 million for Q1 2025.